[1] [9] The medication should only be used under medical supervision as part of a comprehensive treatment plan for type 2 diabetes
Perhaps this may be in part due to high cost, concerns related to surgical intervention, and lack of access to bariatric centers [7]
The "minimal initial benefit" group (approximately 5-10% of users) reported limited improvements during treatment making discontinuation effects irrelevant, typically explained by inadequate product quality with degraded or low-concentration GHK-Cu, inappropriate application technique reducing absorption, unrealistic expectations exceeding what any topical can achieve, severe underlying pathology requiring medical intervention beyond cosmetic peptides, or individual non-responsiveness to copper peptide treatment for genetic or physiological reasons
Coverage under government plans is mixed
Paracrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in mice
In this article, we'll break down what they are, how they work, and why theyre both worth knowing about